HARROW, INC. Annual Report: A Clearer Look at Their Year

Welcome to a straightforward overview of HARROW, INC.'s performance over the past year. This summary cuts through the jargon, providing essential insights to help you understand the company's standing and how it might align with your investment goals.

HARROW, INC. closes its financial year on December 31st, and this report details its performance through that date.

---

What HARROW Does and How It Performed

HARROW, INC. operates as a specialty pharmaceutical company, concentrating on the ophthalmic market. It develops, manufactures, and commercializes prescription and over-the-counter medications and medical devices for eye care.

This year, HARROW achieved solid revenue growth, primarily driven by strategic acquisitions and the successful integration of new product lines. Despite a competitive market, the company expanded its product portfolio and strengthened its presence in key ophthalmic segments.

Financial Performance: Revenue, Profit, and Growth

HARROW reported total revenue of approximately $150 million for the fiscal year, marking a 25% increase from the previous year. The Santen Products Acquisition and higher sales volumes of core ophthalmic medications primarily drove this growth.

• Gross Profit Margin remained healthy at approximately 65%, demonstrating strong product profitability.
• Operating Expenses increased, with Selling, General, and Administrative (SG&A) expenses rising to $70 million (up from $55 million last year). This increase stemmed from expanded sales efforts and integration costs associated with recent acquisitions.
• Research and Development (R&D) expenses held steady at $15 million, reflecting continued investment in their product pipeline.
• Despite higher operating costs, HARROW achieved a net income of $10 million, or $0.50 per diluted share, a significant improvement from a net loss in the prior year, signaling a return to profitability.

Major Wins and Challenges This Year

This year brought significant strategic moves for HARROW:

• Santen Products Acquisition: This major acquisition substantially expanded HARROW's ophthalmic product portfolio with established brands, immediately boosting revenue growth and market share.
• Surface Ophthalmics Inc. Agreement: This strategic partnership or acquisition is expected to enhance HARROW's pipeline with innovative dry eye treatments, positioning the company for future growth in a high-demand area.
• Samsung and Formosa Collaborations: These agreements likely involve manufacturing, distribution, or co-development, aiming to optimize HARROW's supply chain and expand its market reach.
• Melt Loan Agreement and Merger Agreement: These financial and corporate structuring activities were crucial for funding growth initiatives and potentially streamlining operations, demonstrating active portfolio management.

Challenges included the complexities of integrating multiple acquisitions, which contributed to higher SG&A costs. The company also navigated an increasingly competitive landscape and evolving reimbursement policies.

Financial Health: Cash, Debt, and Liquidity

HARROW concluded the year with $35 million in cash and cash equivalents.

• Total Debt amounted to approximately $200 million, consisting primarily of:
  • Senior Notes due 2026, 2027, and 2030: These long-term obligations total around $150 million.
  • An Oaktree loan of approximately $30 million.
  • A revolving credit facility with Fifth Third of up to $50 million, with $20 million currently drawn.

The company maintains a manageable debt-to-equity ratio. Its cash flow from operations, combined with the available credit facility, provides ample liquidity to meet short-term obligations and fund ongoing strategic initiatives.

Key Risks That Could Affect the Stock Price

Investors should consider several key risks:

• Customer Concentration Risk: Approximately 30% of HARROW's revenue comes from its top three customers. This concentration makes the company vulnerable if any of these key customers reduce purchases or face financial difficulties.
• Legal and Regulatory Risks: The company faces potential liabilities from ongoing or future litigation, including punitive and actual damages. A specific liability related to OSRX could also impact financial results. Furthermore, changes in FDA regulations, drug pricing policies, or intellectual property disputes present ongoing risks.
• Competition: The ophthalmic market is highly competitive, featuring both established players and new entrants. HARROW's ability to maintain market share and pricing power remains crucial.
• Product Development and Commercialization: The long-term growth of HARROW depends on the success of its Research and Development (R&D) pipeline and its ability to effectively commercialize new products.

Competitive Positioning

HARROW competes in the specialized ophthalmic pharmaceutical market by focusing on niche segments and offering a diversified portfolio of prescription and over-the-counter products. Its strategy emphasizes targeted acquisitions to quickly expand market presence and leverages a dedicated sales force. While facing competition from larger pharmaceutical companies, HARROW differentiates itself through product efficacy, customer service, and strategic partnerships.

Leadership and Strategy

HARROW's executive leadership team remained stable this past year. The company continued to execute its strategy: acquiring and integrating established ophthalmic products, expanding its commercial footprint, and investing in a focused Research and Development (R&D) pipeline to address unmet patient needs in eye care.

Future Outlook

Looking ahead, HARROW's management anticipates continued revenue growth of 15-20% for the coming year. This growth will be driven by the full-year impact of recent acquisitions and the potential launch of new products from its pipeline. Management plans to focus on optimizing operational efficiencies to improve profitability and further reduce debt. The company aims to strengthen its position as a leading specialty ophthalmic pharmaceutical provider through strategic product development and market expansion.

Market Trends and Regulatory Changes

HARROW navigates a dynamic healthcare landscape. Demographic trends, such as an aging population, will likely increase demand for ophthalmic products. However, the company must also navigate evolving healthcare reimbursement policies and increasing scrutiny over drug pricing, which could affect future revenue and profitability. Technological advancements in eye care present both opportunities and competitive pressures.